What Kowa Pharmaceuticals does

Kowa Pharmaceuticals America, Inc. is a U.S. specialty pharmaceutical subsidiary of Kowa Company, Ltd., a privately held Japanese conglomerate founded in 1894 and headquartered in Nagoya, Japan. Established in 2008 and based in Montgomery, Alabama, the company is currently transitioning from its cardiometabolic heritage—represented by the marketed statin LIVALO (pitavastatin)—toward an ophthalmology-focused portfolio led by NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop that combines FP prostanoid receptor agonism with nitric oxide donation to lower intraocular pressure in open-angle glaucoma and ocular hypertension. The NDA for NCX 470 was submitted to the FDA on July 1, 2026, with expected approval in mid-2027 and U.S. commercial launch before year-end 2027. The company holds worldwide exclusive development and commercialization rights to NCX 470 in the U.S., Japan, and rest of world under a July 2025 licensing agreement with Nicox SA, with 8% royalties on U.S. net sales and up to €127 million in potential milestones; China, Korea, and Southeast Asia rights are held by Ocumension Therapeutics.

The broader pipeline includes Ripasudil, a Rho kinase inhibitor filed in Vietnam for glaucoma and in Phase III for Fuchs endothelial corneal dystrophy in the U.S. and Europe, plus a preclinical collaboration with Glaukos on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor. The company additionally leverages its sister Kowa Optimed division to offer ophthalmic diagnostic equipment, creating a combined prescription therapy and diagnostic platform for eye care providers. Revenue is generated through U.S. pharmaceutical product sales (cardiology and eye care), licensing royalties from NCX 470 starting in 2027, and milestone payments. Go-to-market is executed through a U.S. field sales organization, Medical Science Liaisons engaging Key Opinion Leaders, participation in major ophthalmology conferences (e.g., American Glaucoma Society), and scientific publications, with products distributed through standard pharmaceutical wholesale and retail pharmacy channels. The company serves ophthalmologists, glaucoma specialists, optometrists, and ultimately patients with glaucoma, ocular hypertension, and cardiometabolic conditions. Two wholly-owned subsidiaries—Kowa Research Institute and Kowa Science Institute—support U.S. clinical and translational research.

Name

Kowa Pharmaceuticals

Legal name

Kowa Pharmaceuticals America, Inc.

Website

https://kowapharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

251–500 employees

Short description

Kowa Pharmaceuticals America is a U.S. subsidiary of Japan's Kowa Company that develops and markets ophthalmic therapies, with lead asset NCX 470 (a nitric oxide-donating bimatoprost for glaucoma) pending FDA approval in mid-2027 and a legacy cardiometabolic product, LIVALO.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

Keywords

• Ophthalmic pharmaceuticals
• Glaucoma therapeutics
• Intraocular pressure drugs
• Cardiometabolic medications
• Ophthalmic diagnostics

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Pharmaceutical product sales: Sales of marketed pharmaceutical products including cardiometabolic therapeutics and eye care products in the United States. Legacy products include LIVALO (pitavastatin) for cholesterol management.
2. Licensing royalties from NCX 470: Kowa receives royalties on net sales of NCX 470 in the U.S. (starting at 8%) and other territories under the July 2025 agreement with Nicox. Total potential milestones under the agreement are valued at €127 million. Expected royalty revenue from 2027 onwards upon FDA approval.
3. Milestone payments: Kowa makes milestone payments to Nicox upon achievement of regulatory and sales milestones. A €5 million milestone payment was triggered by Denali trial results, and a €3 million payment was triggered by NDA submission. Further milestone due upon approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Kowa Pharmaceuticals America develops, licenses, and commercializes prescription pharmaceutical products primarily focused on ophthalmology, with a legacy cardiometabolic product (LIVALO/pitavastatin). The company's pipeline centers on novel glaucoma and ocular hypertension therapeutics, most notably NCX 470, a nitric oxide-donating bimatoprost eye drop, alongside Rho kinase inhibitors. It also distributes ophthalmic diagnostic equipment through its Kowa Optimed division to support eye care providers.

Product overview

Kowa Pharmaceuticals America, Inc. is a U.S. pharmaceutical company transitioning from cardiometabolic therapeutics to eye care and ophthalmology. The company operates a dual portfolio structure consisting of: (1) Marketed Products including LIVALO (pitavastatin) for cardiometabolic management, and (2) a growing Ophthalmology Pipeline with NCX 470 (K-911) as the lead asset - a nitric oxide-donating bimatoprost eye drop for glaucoma that completed Phase III trials and had its NDA submitted in July 2026, targeting approval in mid-2027. Additional pipeline assets include Ripasudil (Rho kinase inhibitor) filed in Vietnam and a separate Rho kinase inhibitor in Phase III for Fuchs endothelial corneal dystrophy. The company also offers Ophthalmic Diagnostics equipment through its Kowa Optimed division, providing diagnostic tools for eye care providers. The portfolio reflects the company's shift from its cardiometabolic heritage toward vision preservation and eye care.

Differentiator

Problem solved

Functional benefit

Brands

• LIVALO: Pitavastatin medication for cardiometabolic health
• Kowa Optimed

Products and services

• LIVALO (pitavastatin) Prescription cardiometabolic therapeutic (HMG-CoA reductase inhibitor / statin) for lipid management in patients requiring cholesterol-lowering therapy to reduce cardiovascular risk. Marketed to healthcare professionals managing cardiometabolic patients.
• NCX 470 (K-911 / bimatoprost grenod) Novel nitric oxide (NO)-donating bimatoprost ophthalmic solution 0.1% for once-daily topical treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Combines FP prostanoid receptor agonism with nitric oxide donation for enhanced IOP reduction. Licensed to Kowa for the U.S., Japan, and rest of world.
• Ripasudil (Rho kinase inhibitor) Rho kinase (ROCK) inhibitor ophthalmic therapy for the treatment of glaucoma and ocular hypertension, offering an alternative mechanism of action for IOP reduction beyond prostaglandin analogs.
• Rho kinase inhibitor for Fuchs endothelial corneal dystrophy Rho kinase inhibitor candidate in Phase III development in the U.S. and Europe for the treatment of Fuchs endothelial corneal dystrophy, a progressive eye disease affecting the corneal endothelium.
• Ophthalmic Diagnostic Equipment (Kowa Optimed) Diagnostic equipment and tools for ophthalmic conditions, distributed through the Kowa Optimed division of Kowa Company, Ltd. Provides diagnostic standards and solutions for eye care providers, supporting the detection and management of ocular disease.

Quantifiable outcome

• IOP reduction of 7.9 to 10.0 mmHg for NCX 470 vs. 7.1 to 9.8 mmHg for latanoprost (standard of care)
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core/flagship and minor.

• Nicox SAcore/flagshipOEM/ Whitelabel/ Licensing Partner · 17 July 2025Strategic licensing partnership for NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop for glaucoma. Kowa holds exclusive rights to develop and commercialize NCX 470 in the U.S., Japan, and rest of world. Royalties on net sales start at 8% in the U.S. Total potential milestones valued at €127 million. NDA submitted to FDA in July 2026 with expected approval mid-2027.
• Ocumension Therapeuticscore/flagshipStrategic or Co-development Partner · 17 July 2025Co-development partner for NCX 470 in China, Korea, and Southeast Asia. Ocumension co-funded the Denali Phase 3 trial and holds exclusive rights for these markets. Nicox receives royalties of 6% to 12% on net sales in these territories. Regulatory submission activities in China expected to follow the U.S. NDA filing.
• Kowa Optimed (Ophthalmic & Medical Equipment Division)core/flagshipTechnology or IntegrationInternal division of Kowa Company, Ltd. focused on ophthalmic diagnostics and medical equipment. Sets diagnostic standards for ophthalmic conditions and provides diagnostic tools for eye care providers. Part of the broader global network dedicated to ocular health that Kowa Pharmaceuticals America works alongside.
• Glaukos CorporationminorStrategic or Co-development PartnerPreclinical research collaboration on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, being developed with Glaukos for potential ophthalmic applications.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Santen Pharmaceutical Co., Ltd. Japanese specialty pharmaceutical company focused on ophthalmology with a broad portfolio of prescription eye care products across glaucoma, dry eye, and other indications. Closest direct analog to Kowa Pharmaceuticals America given the Japanese-headquartered specialty ophthalmology pharma model with US commercialization operations.
• Nicox SA: French ophthalmology R&D company that originated NCX 470 and licensed it to Kowa. Specialty ophthalmology focus with glaucoma pipeline (NCX 470, NCX 1728) makes it a direct functional peer despite being earlier-stage and primarily R&D-focused rather than commercial.
• Glaukos Corporation: US-based ophthalmology company focused on glaucoma and corneal health with surgical device portfolio (MIGS stents) and emerging pharmaceutical pipeline. Partner with Kowa on NCX 1728 and directly comparable as a glaucoma-focused ophthalmology specialist with both device and pharmaceutical ambitions.

Broad incumbents

• Allergan (AbbVie): Major global pharmaceutical company with leading glaucoma franchise (Lumigan/bimatoprost, Alphagan, Combigan) acquired through Allergan. Direct incumbent competitor to NCX 470 since Lumigan uses the same bimatoprost base, and AbbVie has substantially deeper commercial reach in ophthalmology.
• Alcon Inc. World's largest eye care device company with a substantial pharmaceutical franchise including glaucoma products (acquired Aerie Pharmaceuticals' Rhopressa/Rocklatan in 2020). Broad incumbent across both surgical and pharmaceutical ophthalmology with deep commercial relationships.
• Bausch + Lomb (Bausch Health): Major global ophthalmology company with broad portfolio spanning pharmaceuticals, surgical devices, and consumer eye care products. Includes Vyzulta (latanoprostene bunod) as a competing nitric oxide-donating glaucoma therapy, making it particularly relevant as both an incumbent and a mechanism-of-action competitor.
• Teva Pharmaceutical Industries Ltd. Global pharmaceutical company with established ophthalmology franchise including generic and branded products for glaucoma and other eye conditions. Broad incumbent in ophthalmology pharmaceuticals with extensive commercial reach and generic competition to branded therapies.

Emerging players

• Ocular Therapeutix, Inc. US-based specialty ophthalmology company developing sustained-release drug delivery platforms for various eye conditions including glaucoma. Smaller and earlier-stage than Kowa Pharmaceuticals America but operates with similar specialty ophthalmology focus and US-based commercialization model.
• Kala Bio, Inc. US-based specialty ophthalmology company developing innovative therapies for ocular surface diseases and retinal conditions. Smaller commercial-stage company with similar specialty pharma positioning in ophthalmology, though focused on different therapeutic areas than Kowa's glaucoma portfolio.
• Apellis Pharmaceuticals, Inc. US-based specialty ophthalmology company focused on retinal diseases (geographic atrophy, macular degeneration) with approved product (Syfovre/Empaveli). Comparable specialty ophthalmology commercial-stage company with novel mechanism therapies, though focused on posterior segment rather than glaucoma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kowapharmaceuticalsamericainc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kowa Pharmaceuticals